FHTX Foghorn Therapeutics Inc.

FDA Catalyst Company
12.05
+0.78  (+7%)
Previous Close 11.27
Open 11.5
52 Week Low 8.01
52 Week High 24.34
Market Cap $499,687,086
Shares 41,467,808
Float 23,929,451
Enterprise Value $329,088,032
Volume 39,943
Av. Daily Volume 149,888
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/15/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/22/2021
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/23/2021
Wedbush Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/17/2020
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/17/2020
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/17/2020
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/17/2020

Latest News

  1. - Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial clinical data expected for FHD-286 in H2 2022 and FHD-609 in 2023

    - New preclinical data for FHD-286 presented at AACR provides mechanistic understanding of anti-tumor activity and supports clinical development in AML

    - More than 10 programs in pre-clinical pipeline evaluating targeted protein degraders, enzymatic inhibitors and transcription factor disruptors, including the BRM-selective inhibitor program

    - Cash, cash equivalents and marketable securities of $424.7 million, as of March 31, 2022, provides significant cash runway

    CAMBRIDGE…

    View Full Article
  2. CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced preclinical data supporting the clinical development and mechanistic understanding of BAF inhibition through the BRG1 (SMARCA4) and BRM (SMARCA2) dual inhibitor, FHD-286, for the treatment of cancer, at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. FHD-286 has first-in-class potential and is Foghorn's first candidate directly targeting the chromatin regulatory system to emerge from the Company's Gene Traffic Control®…

    View Full Article
  3. CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the company will have an oral and late-breaking poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. Presentations include preclinical data supporting the clinical development of the novel BAF inhibitor FHD-286 for the treatment of acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) and metastatic uveal melanoma (UM).

    Oral Presentation Details
    Abstract ND14

    View Full Article
    • Allan Reine joins the Board as independent Non-Executive Director
    • Brings significant experience as CFO of NASDAQ-listed biotechs, where he helped raise over $700 million
    • Over 20 years in the biotechnology industry with relevant experiences as a biotech CFO, portfolio management, sell-side analyst and investment banking

    GALWAY, Ireland and SAN DIEGO, March 23, 2022 /PRNewswire/ -- ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced that it has appointed Allan Reine as independent Non-Executive Director to its Board.

    Dr. Reine brings significant experience to ONK Therapeutics' Board from both the life sciences industry and in financial…

    View Full Article
  4. CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will participate at the 2022 Guggenheim Targeted Protein Degradation Day which is being held virtually on March 16th, 2022. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

    Fireside chat date and time: Wednesday, March 16th, 2022, at 9:30 a.m. ET

    Please find a link to the fireside chat here.

    The webcast…

    View Full Article
View All Foghorn Therapeutics Inc. News